Gentler radiation may boost lymphoma treatment without harsh side effects
NCT ID NCT04054167
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This phase II trial tests whether ultra low dose radiation, given before or after chemotherapy-free targeted therapy, can help control mantle cell lymphoma that has returned or stopped responding to treatment. About 51 adults with measurable disease will receive the radiation, and doctors will check tumor shrinkage at 3 months. The goal is to improve response while reducing side effects compared to standard high-dose radiation.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ultra low dose radiation therapy
What this could lead to
If successful, this approach could offer a gentler way to control mantle cell lymphoma when standard treatments stop working, potentially improving quality of life.
What could go wrong
This is a small, early-phase trial (51 participants) with no control group, so results may not apply broadly. The radiation is ultra low dose, but its long-term effectiveness and safety are still uncertain.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT MANTLE CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States